Catalyst Wire Dossier Catalyst Wire Dossier

Navtemadlin

navtemadlin · Kartos Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Navtemadlin, covering 2023-03-02 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia [Phase 1]

See pricing